Wegovy Stepped Care and the Off-Ramp: What Coming Off Actually Looks Like for Teens

Most teens on Wegovy will eventually step down. The step-down has structure: readiness criteria, a gradual transition, continued lifestyle work, and ongoing monitoring. Parents rarely see that structure described in plain language. This page walks through the protocol a pediatric obesity medicine specialist follows when a teen comes off Wegovy. It also covers what the evidence does and does not yet say about what happens next.

Why obesity is treated as a chronic condition (and what that means for medication)

The American Academy of Pediatrics (AAP), the American Medical Association, and the World Health Organization all classify obesity as a chronic disease. That language matters. A chronic disease is something the body manages over time, like asthma, type 1 diabetes, or high blood pressure. It is not a willpower problem.

Chronic conditions get chronic management. That can mean a daily inhaler, an insulin pump, or a course of medication followed by a planned step-down and watchful follow-up. The same logic applies in pediatric obesity medicine.

This is the answer to the "forever-drug" worry: chronic management is not a life sentence with one medicine. It is a layered plan with planned step-ups and step-downs. Wegovy can be part of that plan for a teen who needs it. Coming off Wegovy can also be part of that plan, when the time is right.

What "stepped care" actually means in pediatric obesity medicine

Stepped care is the framework the AAP set out in its 2023 obesity guideline. The AAP recommends offering treatment early and at the appropriate intensity, not watchful waiting. For eligible teens, medication is offered as a concurrent adjunct to lifestyle treatment, not held in reserve until lifestyle work alone has failed. Step down when readiness criteria are met.

In pediatric obesity care, the stepped-care ladder looks like this:

1. Intensive Health Behavior and Lifestyle Treatment (IHBLT) alone. This is structured family-based work on eating patterns, physical activity, sleep, and behavioral skills, guided by a pediatric specialist.
2. IHBLT plus medication (such as Wegovy, also called semaglutide, a GLP-1 receptor agonist that lowers appetite and slows stomach emptying). The AAP recommends weight-loss pharmacotherapy for adolescents 12 and older with obesity (BMI at or above the 95th percentile) as an adjunct to lifestyle treatment, not as a replacement for it.
3. IHBLT plus medication plus metabolic or bariatric surgery, reserved for severe cases.

Notice what is true at every step: IHBLT is the base layer. It does not stop when medication is added. It does not stop when medication is removed. That single design choice is the answer to most parent worries about the GLP-1 transition.

What transitioning off a GLP-1 actually looks like

If the time comes to transition off Wegovy, it is not a single decision made on a single day. It is a process with criteria, a transition, and a maintenance plan. Here is how a pediatric obesity medicine specialist thinks about each piece.

GLP-1 transition criteria: when transitioning down is on the table

Before talking about coming off the medication, a pediatric specialist looks for several signals:

• Goal weight maintained for at least six months. Stable, not still climbing or still falling fast.
• Comorbidities improved or resolved. Examples include prediabetes, high blood pressure, sleep apnea, or fatty liver. If these were the reason for the medication, are they better now?
• Teen and family ready. Pediatric obesity care is family-system care. The decision involves the teen, the parents, and the clinical team together.
• Specialist clinical judgment. This is not a calendar countdown. It is a judgment call by a doctor who knows the teen and the family.

To be transparent: "GLP-1 transition criteria" as written above is how Balance approaches the conversation. It is not a published national guideline. The AAP guideline is clear on stepped care in general. The specific criteria for transitioning down GLP-1 medication in adolescents are still being defined in pediatric obesity practice.

What the transition looks like

Stopping Wegovy is not done abruptly. The transition is usually a gradual dose reduction across several months. During that window:

• IHBLT continues unchanged. The lifestyle work that has been part of the plan from day one carries through the transition and into maintenance.
• Biometric monitoring increases. That means more frequent weight, BMI, and growth checks, plus repeat labs for any markers that were elevated before.
• Family check-ins are scheduled, not optional. Appetite changes, eating patterns, mood, and any signs of restrictive or binge-pattern eating get screened actively during the transition window.
• The clock is flexible. If something on a check-in suggests the teen is not ready, the transition pauses. The plan adjusts.

To be honest about the evidence: transition protocols in adolescents are extrapolated from adult practice. There is not yet a published adolescent-specific transition schedule from a randomized controlled trial. Pediatric obesity medicine specialists build the transition plan from AAP framework principles, adult experience, and what the individual teen needs.

“One of my favorite success stories is a patient who reached their goal weight and, more importantly, built sustainable habits that made long-term success possible. Throughout treatment, we focused on balanced nutrition, consistent physical activity, and creating routines they could realistically maintain. Their family was all in—encouraging healthy meals, joining walks, and celebrating progress every step of the way. Rather than stopping the GLP-1 abruptly, we took a slow, intentional approach, gradually reducing the dose every 2–4 weeks while closely monitoring for weight regain. Just as we carefully ramped the medication up, we deliberately transitioned it down. That thoughtful approach, combined with strong lifestyle habits and family support, allowed the patient to successfully maintain their weight without medication.”

Dr. Makia Powers, MD, DABOM

What happens if weight regain occurs

Some weight regain after stopping a GLP-1 medication is expected based on adult data. The adolescent picture is still being filled in. Two things matter here:

1. Regain is not failure. It is information. It tells the team whether the maintenance plan is holding or whether the body needs more support.
2. Re-initiation is on the table. If regain is gradual and manageable inside the IHBLT plan, the team adjusts the lifestyle layer. If regain is rapid or comorbidities return, the medication can be restarted. That is what makes this stepped care, not one-and-done.

The role of the IHBLT base layer is exactly to keep the trajectory readable. A family that has been doing structured lifestyle work for months or years has a clearer view of what is changing post-medication. A family that starts lifestyle work only after stopping does not have that baseline.

What the evidence actually says about weight regain after stopping

The largest pediatric study of Wegovy is the STEP TEENS trial (NEJM 2022). It enrolled 201 adolescents and ran for 68 weeks on treatment. At week 68, teens on semaglutide reduced BMI by about 16% (-16.1%), while teens on placebo slightly increased BMI (+0.6%). STEP TEENS was an on-treatment trial: it did not follow teens for a year after stopping the medication. A 7-week off-treatment extension did show a small BMI regain. The trial authors named this as a limitation themselves.

The most-cited regain numbers come from the adult STEP 1 extension. In that study, adults regained about two-thirds of the weight they had lost in the year after stopping semaglutide. That number is widely shared in news coverage and parent groups. There is a structural caveat that gets left out: the STEP 1 extension stopped the lifestyle support at the same time as the medication. Whatever the regain pattern shows, it shows what happens when both layers of stepped care are removed at once. It does not show what happens when only the medication is removed and the lifestyle layer continues.

The pediatric Balance protocol does not stop the lifestyle layer at GLP-1 transition. That is the structural reason the adult regain number is not a direct prediction for teens on this plan.

The long-term evidence base for what happens after adolescents step off Wegovy is still being built. Pediatric systematic reviews flag this as a major gap that needs urgent research. We will keep updating this page as adolescent follow-up data is published.

How Blueberry's stepped care is structured day-to-day

For families inside Blueberry's pediatric obesity program, stepped care is not an abstract framework. It is a weekly rhythm.

• The IHBLT base layer runs at the cadence the family and the specialist set, focusing on eating patterns, activity, sleep, and behavioral skills. It does not change when medication is added or removed.
• The pharmacotherapy layer, when added, is overseen by a pediatric specialist (not a general telehealth prescriber). Titration is slow. Biometric checks are scheduled. Side effects are managed against the medication's known profile, which includes an FDA boxed warning for risk of thyroid C-cell tumors; Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.
• The behavioral health layer screens for disordered eating across the whole journey, especially during dose changes. Screens like SCOFF, EDS-PC, and ADO-BED are part of pediatric practice.
• The maintenance and GLP-1 transition layers are explicit, planned, and named.

This is what "pediatric obesity medicine specialist oversight" actually buys families. The team treats the GLP-1 transition as a clinical event, not the end of the relationship.

When transitioning off medication entirely is the right call, and how Blueberry supports that

Some families decide that pharmacotherapy is not the right path for their teen. That is a valid clinical decision, especially when comorbidities are mild or when the family prefers a lifestyle-only approach.

Blueberry runs a lifestyle-only program that uses the same IHBLT base layer without the medication layer. Same pediatric specialist oversight. Same family-system care. Same behavioral foundation.

This matters for two reasons. First, it gives families a real non-medication path with the same clinical depth. Second, it means the GLP-1 transition described in this article connects to something concrete. A teen who comes off Wegovy can step directly into the lifestyle-only program. The care team and the behavioral structure are already in place.

What pediatric specialty matters most for this question

Adult Wegovy prescribing in the current telehealth landscape often stops at the script. A patient fills the prescription, takes the medication, and when she chooses to stop, the relationship effectively ends.

Pediatric obesity medicine treats the GLP-1 transition as part of the care, not the end of it. The lifestyle layer continues, monitoring intensifies, behavioral health stays engaged, and the family check-ins keep happening on schedule.

For a teenager who is still growing and still building bone and muscle, that structure is standard of care. A board-certified pediatric obesity medicine specialist (a DABOM diplomate, like Dr. Makia Powers) is trained to lead this process with the adolescent body and the family system in mind.

Frequently asked questions

Do you have to take Wegovy forever?

No. Wegovy is part of a stepped-care plan for a chronic condition. The goal is the right intensity of treatment at the right time. A planned GLP-1 transition, with criteria and a gradual transition, is part of the framework. Some teens may need medication for a defined period and then step down. Others may need it longer. The decision is clinical, family-system aware, and reviewed regularly.

Will my teen gain the weight back if she stops Wegovy?

Some regain is possible. Adult data (the STEP 1 extension) showed that adults regained about two-thirds of their lost weight in the year after stopping semaglutide. That extension also stopped the lifestyle support at the same time. The pediatric Balance protocol keeps the lifestyle layer going through and after the transition. That is the structural reason adult regain numbers are not a direct prediction for teens on this plan. Long-term adolescent data is still being built. The maintenance and re-initiation plan exists to manage that uncertainty responsibly.

What is "stepped care" in pediatric obesity treatment?

Stepped care is the AAP 2023 framework for pediatric obesity. The AAP recommends offering treatment early and at the appropriate intensity, not watchful waiting. For eligible teens, medication is offered as a concurrent adjunct to lifestyle treatment, not held in reserve until lifestyle work alone has failed. The base layer is intensive lifestyle treatment (IHBLT). Medication is added on top when clinically indicated. The lifestyle layer continues at every step, including after medication is reduced or stepped down.

How long is the Wegovy transition for teens?

There is no published adolescent-specific transition schedule. In pediatric obesity practice, the transition is gradual, usually across several months. The dose steps down in planned reductions while lifestyle work and monitoring continue. The exact pace is individualized by the pediatric specialist. It is based on the teen's response, comorbidity trajectory, and family-system readiness.

Can my teen ever stop Wegovy and stay off?

The honest answer is "it depends," for three reasons. First, whether the GLP-1 transition criteria are met (goal weight stable, comorbidities improved, family ready). Second, what the IHBLT base layer is doing post-transition. Third, how the teen's body responds. Some teens stay off after a planned transition. Others step back on later. Either outcome is part of stepped care.

Is the Blueberry lifestyle-only program an alternative to Wegovy?

Yes. The Blueberry lifestyle-only program runs the same IHBLT base layer with the same pediatric specialist oversight, without the medication layer. Families choose it for many reasons: mild comorbidities, family preference, or a planned post-Wegovy maintenance plan. It is also the path families step into when they come off medication and want to keep the lifestyle structure intact.

Talk to a pediatric obesity specialist about a stepped-care plan

You may be weighing whether Wegovy is right for your teen. Or you may be trying to plan a responsible GLP-1 transition from a medication she is already taking. Either way, the most useful next step is a conversation with a pediatric obesity medicine specialist. That clinician can look at the whole picture: growth, comorbidities, family-system context, and behavioral health.

Sources

1. Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022;387(24):2245–2257. doi:10.1056/NEJMoa2208601
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183
3. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564. doi:10.1111/dom.14725
4. Hampl SE, Hassink SG, Skinner AC, et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity. Pediatrics. 2023;151(2):e2022060640. doi:10.1542/peds.2022-060640
5. Bartkoski M, Poweleit EA, Stancil SL. GLP-1 Agonists for Pediatric Psychopharmacology: Opportunities and Cautions. Clin Transl Sci. 2025;18(6):e70262. doi:10.1111/cts.70262
6. Torbahn G, Lischka J, Brown T, et al. Anti-Obesity Medication in the Management of Children and Adolescents With Obesity. Clin Endocrinol (Oxf). 2025;102(1):51–61. doi:10.1111/cen.15133
7. Zaitoon H, Wauters AD, Rodriguez LM, Lynch JL. Beyond Weight Loss: Optimizing GLP-1 Receptor Agonist Use in Children. Children (Basel). 2025;12(11):1427. doi:10.3390/children12111427
8. U.S. Food and Drug Administration. WEGOVY® (semaglutide injection) Prescribing Information.